Griffin Discoveries will present and discuss their dual-action H1R/H4R receptor antagonist strategy for the treatment of ocular allergy. In a recent collaboration with the world leading ophthalmic CRO Ora clinical, Griffin Discoveries has established a compelling pre-clinical proof of concept in a murine model for ocular allergy. Griffin’s compounds displayed a rapid onset of action with a sustained effect on ocular redness, thereby mimicking both the actions of selective H1R antagonists and ocular steroids.

For more information on the conference please visit: http://www.healthtech.com/Targeting-Ocular-Disorders/